Picture a house party where one guest has commandeered the speakers, the kitchen, and most of the conversation. Everyone else is still there, still drinking, still talking. They’re just doing it at normal volume in the corner while the loud guy explains his vision. That’s roughly what venture capital looks like right now, and biotech is the person in the corner having a perfectly reasonable evening.
The headlines this cycle read like a coronation. North American startup funding shattered records in the first half of 2026, driven by AI. European startup funding hit a six-year low in deal count while AI absorbed 60 percent of the money. Emerging markets VC rebounded on a China tech surge. And then, tucked in beneath all of that noise, a line that I find far more interesting than any of it: biotech startup investment held steady.
Steady Is Not a Consolation Prize
I review AI tools for a living. I spend my days watching demos that promise the world and deliver a wrapper around someone else’s model. So let me be clear about my bias before I go further: I am deeply suspicious of any sector where the money grows faster than the substance.
Held steady, in a period where one category is vacuuming up the oxygen in the room, is not a failure signal. It’s evidence of a funding base that isn’t reacting to vibes. Biotech valuations don’t get to inflate on the strength of a keynote. Something either passes a trial or it doesn’t. That constraint is annoying if you’re a founder trying to raise, and it’s the reason the numbers look boring instead of parabolic.
Meanwhile, BioPharma Dive reports the biotech funding gap is widening even as VC investment overall rebounds. So the picture isn’t rosy. Steady at the top line can hide real pain underneath it — money concentrating into fewer, later-stage, safer bets while earlier work struggles to find a check. That’s the same dynamic hollowing out European deal counts, just with different scenery.
What the European Number Actually Tells Us
Sixty percent of European funding going to AI, alongside a six-year low in deal count, is the single most useful data point in this whole set. Fewer deals, more money per deal, concentrated in one category. That is not a growing market. That is a narrowing one wearing a growing market’s clothes.
When capital concentrates like that, a few things follow with grim reliability:
- Valuations decouple from revenue because the comparison set is other AI companies, not other businesses.
- Non-AI founders start bolting AI language onto products that don’t need it, purely as a fundraising tactic.
- Category discipline erodes, because there’s no room for a skeptic when everyone’s marking the same book up.
I see the second one constantly. Half the “AI agents” that land in my inbox are workflow tools that added a chat box in the last two quarters. The tool didn’t get better. The pitch deck did.
Why the Boring Sector Deserves a Second Look
Biotech has an accountability mechanism that AI simply does not have yet. A drug candidate either clears its endpoints or it fails publicly and expensively. There is no version of biotech where you ship a demo, generate a wave of screenshots, and coast for eighteen months on the assumption that the hard part will be solved eventually.
AI tooling lives almost entirely in that gap. The gap between what a demo shows and what a product does is where most of the current funding is parked. I’m not saying nothing real is being built — plenty is. I’m saying the sector has no reliable filter, and money flowing in at record pace without a filter produces exactly what you’d expect.
So when I read that biotech held steady, I don’t read stagnation. I read a sector where the money still has to answer to something.
The Test Worth Watching
The interesting question isn’t whether AI funding stays hot. It’s what happens to the companies funded during the concentration peak when their first serious renewal cycle arrives and buyers start asking what the thing actually replaced.
Biotech will still be there, funding roughly what it funded before, running trials that take as long as they take. Unglamorous. Slow. Governed by evidence.
If you build or buy AI tools, that contrast is the useful takeaway. Ask what your evidence standard is. Ask what would have to be true for the tool to fail, and whether anyone is measuring it. The sectors that can answer those questions tend to survive their own hype cycles. The ones that can’t just get quieter, later, and all at once.
🕒 Published: